Clinical trial
A National Multicenter Prospective Cohort Study on the Incidence Characteristics and Risk Associations of Metabolic and Multi-system Comorbidities in Overweight and Obese Populations Stratified by Body Mass Index
NCT07884903 is registered in ClinicalTrials.gov with Shanxi Bethune Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A National Multicenter Prospective Cohort Study on the Incidence Characteristics and Risk Associations of Metabolic and Multi-system Comorbidities in Overweight and Obese Populations Stratified by Body Mass Index
- Lead sponsor
- Shanxi Bethune Hospital
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- November 1, 2026
- Completion date
- September 30, 2029
- Enrollment
- 25,974 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
cardiovascular diseases, diabetes mellitus, type 2, dyslipidemias, hypertension, hyperuricemia, non-alcoholic fatty liver disease (masld), obesity & overweight, polycystic ovary syndrome, sleep apnea, obstructives
Arms
As registered; 4 arms.
-
Overweight
Adults with BMI 23.0-27.4 kg/m². Target enrollment: 7,785 participants.
-
Mild Obesity
Adults with BMI 27.5-32.4 kg/m². Target enrollment: 7,785 participants.
-
Moderate Obesity
Adults with BMI 32.5-37.4 kg/m². Target enrollment: 7,785 participants.
-
Severe Obesity
Adults with BMI ≥37.5 kg/m². Target enrollment: 2,544 participants.
Primary endpoints
Registered primary outcome measures; 4 primary.
-
Incidence of Type 2 Diabetes Mellitus
3-year incidence of new-onset type 2 diabetes mellitus diagnosed according to ADA criteria (fasting glucose ≥7.0 mmol/L, HbA1c ≥6.5%, or 2h OGTT ≥11.1 mmol/L)
-
Incidence of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
3-year incidence of new-onset MASLD diagnosed by abdominal ultrasound and/or FibroScan with hepatic steatosis, excluding other causes of liver disease
-
Incidence of Hypertension
3-year incidence of new-onset hypertension (systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg on at least 2 occasions, or initiation of antihypertensive medication)
-
Incidence of Atherosclerotic Cardiovascular Disease (ASCVD)
3-year incidence of ASCVD events including coronary heart disease, cerebral infarction, transient ischemic attack (TIA), and peripheral artery disease, confirmed by clinical diagnosis and imaging
Lead sponsor's other trials
Shanxi Bethune Hospital, most recent start first.
+17 more trials See the organization page
Similar trials
Same condition (Hyperuricemia) and phase, most recent start first.
+35 more trials See the condition page